96.11
-1.28 (-1.31%)
| Penutupan Terdahulu | 97.39 |
| Buka | 97.05 |
| Jumlah Dagangan | 2,097,614 |
| Purata Dagangan (3B) | 981,669 |
| Modal Pasaran | 23,110,174,720 |
| Harga / Pendapatan (P/E Ke hadapan) | 7.04 |
| Harga / Jualan (P/S) | 6.77 |
| Harga / Buku (P/B) | 1.16 |
| Julat 52 Minggu |
| Margin Keuntungan | -27.89% |
| Margin Operasi (TTM) | -270.46% |
| EPS Cair (TTM) | -3.72 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -2.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -43.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.55% |
| Nisbah Semasa (MRQ) | 10.18 |
| Aliran Tunai Operasi (OCF TTM) | -255.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -335.98 M |
| Pulangan Atas Aset (ROA TTM) | -3.67% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.94% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | BioNTech SE | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.75 |
|
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 62.69% |
| % Dimiliki oleh Institusi | 22.24% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Flossbach Von Storch Se | 30 Sep 2025 | 4,230,033 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 140.00 (HC Wainwright & Co., 45.67%) | Beli |
| Median | 125.50 (30.58%) | |
| Rendah | 117.00 (UBS, 21.74%) | Pegang |
| Purata | 127.00 (32.14%) | |
| Jumlah | 2 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 103.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Nov 2025 | 140.00 (45.67%) | Beli | 105.07 |
| 08 Sep 2025 | 136.00 (41.50%) | Beli | 102.66 | |
| UBS | 06 Nov 2025 | 117.00 (21.74%) | Pegang | 103.35 |
| JP Morgan | 23 Oct 2025 | 120.00 (24.86%) | Pegang | 104.75 |
| 22 Sep 2025 | 121.00 (25.90%) | Pegang | 98.72 | |
| Morgan Stanley | 10 Oct 2025 | 131.00 (36.30%) | Beli | 102.06 |
Tiada data dalam julat masa ini.
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 02 Jun 2022 | - | 17 Jun 2022 | 2.111 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2022 | 2.11 | 1 | 1.41 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |